Description
EYLEA 40 Injection 1’s are a vital component in the management of neovascular age-related macular degeneration (nAMD) and macular edema following retinal vein occlusion. Each pre-filled syringe contains 0.05 mL of Aflibercept, a recombinant, fusion protein that selectively binds to and neutralizes VEGF-A, VEGF-B, and Placental Growth Factor (PlGF). This targeted action helps reduce retinal fluid and improve vision in affected individuals. Administered via intravitreal injection, EYLEA 40 Injection 1’s are a crucial tool in preserving and enhancing visual acuity for those battling these eye conditions.
Reviews
There are no reviews yet.